Replimune Faces Major Setback After FDA Rejects Lead Cancer Therapy for Second Time
Replimune's stock fell 64% after the FDA rejected its lead cancer therapy, RP1, for the second time, raising concerns about the company's future and financial stability. The rejection has forced management to implement cost-cutting measures, including reducing U.S.-based manufacturing operations. The company's valuation is heavily dependent on the approval of RP1, which has not yet reached commercialization.
Topics: Biotech Cancer Immunotherapy Clinical Trials FDA Rejection Stock Market Reaction